Zai Lab Documents
Documents
0
Ticker
ZLAB
ISIN
US98887Q1040
Zai Lab SEC Filings
Type | Report | Date |
|---|---|---|
| No documents available | ||
Zai Lab Documents 2026
This page contains all official documents and SEC filings for Zai Lab stock (ZLAB, ISIN: US98887Q1040). This includes annual reports (Form 10-K), quarterly reports (Form 10-Q), and insider transactions (Form 4). Currently 0 documents are available. Data is updated regularly to provide investors with a complete overview of Zai Lab's regulatory filings.
Zai Lab Stock analysis
Zai Lab Zai Lab Ltd, based in Pudong, China, is a biopharmaceutical company operating in the Health Care sector. It develops and commercializes innovative treatments for oncology, immunology, neuroscience, and infectious diseases. The company offers products such as Zejula for ovarian cancer, VYVGART for myasthenia gravis, NUZYRA for bacterial infections, Optune for brain tumors, Qinlock for gastrointestinal tumors, Xacduro for bacterial pneumonia, and Augtyro for lung cancer. Zai Lab collaborates with leading pharmaceutical firms including Pfizer and Amgen.